מזומנים למניה אחת Geron Corporation (GERN)

Geron Corporation relies on an asset-light business model, outsourcing production and testing to third-party contractors. The cash per share figure demonstrates the issuer's financial cushion, with 0.46 showing the level of this metric. Patents for hematological developments ensure the company's stability, while an active entry into the myelodysplastic syndromes therapy market expands its base of US clinics.
פילוחים אנליטיים של חברת Geron Corporation

This indicator reflects the volume of liquid assets per common share, allowing for an assessment of the company's financial strength before its capital is exhausted. By analyzing the historical cash per share level, an investor can determine the ability of Geron Corporation (GERN) to fund the expansion of Rytelo into the European market and the development of myelofibrosis research without resorting to expensive external borrowing.